Cargando…
Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for many patients. This study aims to compare the ma...
Autores principales: | Scerni, Ana Carolina Costa, Alvares, Leonardo Azevedo, Beltrão, Ana Cristina, Bentes, Iê Regina, Azevedo, Tereza Cristina, Bentes, Alessandra Quinto, Lemos, José Alexandre Rodrigues |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728184/ https://www.ncbi.nlm.nih.gov/pubmed/19690655 http://dx.doi.org/10.1590/S1807-59322009000800004 |
Ejemplares similares
-
Differentially expressed genes responsible for insensitivity of CD34+ cells to kinase inhibitors in patients with chronic myeloid leukemia
por: Moreira-Nunes, Caroline FA, et al.
Publicado: (2013) -
Impact of Variants in the ATIC and ARID5B Genes on Therapeutic Failure with Imatinib in Patients with Chronic Myeloid Leukemia
por: Cereja Pantoja, Karla Beatriz Cardias, et al.
Publicado: (2022) -
Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia
por: Alves, Raquel, et al.
Publicado: (2022) -
P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023) -
Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)